What is Clascoterone and how does it help male pattern baldness?

Clascoterone is a topical anti-androgen that blocks DHT locally on the scalp, preventing hair follicle miniaturization and promoting hair growth for male pattern baldness.

What were the results of the Clascoterone Phase III trials for hair loss?

The Phase III trials showed significant relative increases in hair count, with one trial reporting a 539% increase compared to placebo over six months.

Is Clascoterone safer than oral medications for hair loss?

Yes, Clascoterone is applied topically and acts locally, aiming to avoid the systemic hormonal side effects often associated with oral anti-androgens like finasteride.

Home / Health / New Hair Loss Drug Shows Major Growth

New Hair Loss Drug Shows Major Growth

8 Dec

•

Summary

Clascoterone shows strong hair growth results in men's baldness trials.
Topical drug blocks DHT locally, avoiding systemic hormonal side effects.
Trials show significant hair count increases, with a favorable safety profile.

A potential breakthrough in treating male pattern baldness has emerged with Clascoterone, a topical anti-androgen. Announced by Cosmo Pharmaceuticals in late 2025, the drug delivered strong hair growth results in two Phase III trials. It works by blocking dihydrotestosterone (DHT) directly at the scalp, aiming to restore hair without the systemic hormonal side effects associated with oral treatments.

The recent trials demonstrated significant increases in hair counts compared to placebo, with one reporting a 539% relative increase. Crucially, Clascoterone's topical application and rapid metabolism suggest minimal systemic absorption, leading to a favorable safety profile comparable to placebo and avoiding the risks of oral DHT blockers.

If approved, Clascoterone could be the first new topical treatment in 30 years. While promising, further long-term data and regulatory review are pending. It is expected to benefit men with early to mid-stage androgenetic alopecia seeking a safer, scalp-focused alternative.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.